Lactobacillus rhamnosus GG لـ Antibiotic-Associated Diarrhea (AAD)
AMeta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
الخلاصة
Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.
Key Study Findings
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
مقابل: None
Outcome: Probiotic prescribing habits of Italian PCPs
التأثير: L. rhamnosus GG used by 91.8%
None
المجتمع المدروس: Italian primary care pediatricians
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
مقابل: None
Outcome: Clinical guideline recommendations for pediatric GI
التأثير: None
None
المجتمع المدروس: Pediatric patients with GI disorders
Controlled Clinical Trial
n=24
2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days
مقابل: LPS-only group (no probiotics)
Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines)
التأثير: None
p<0.05 to <0.001
المجتمع المدروس: Male Wistar albino rats with LPS-induced sepsis
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
مقابل: None
Outcome: None
التأثير: None
None
المجتمع المدروس: Pediatric population
Randomized Controlled Trial
Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain)
مقابل: Placebo
Outcome: Antibiotic-associated diarrhea incidence
التأثير: None
None
المجتمع المدروس: Adult patients receiving antibiotics
Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745
مقابل: Placebo or standard care
Outcome: AAD prevention and pediatric gastroenteritis
التأثير: None
None
المجتمع المدروس: AAD and gastroenteritis patients (review)
Key Statistics
20
الدراسات
4000
المشاركون
↑
Positive
A
التقييم
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 اقتباسات
Medicina (Kaunas, Lithuania)
2025
1 اقتباسات
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Cureus
2024
1 اقتباسات
Cureus
2023
19 اقتباسات
Archivos argentinos de …
2022
23 اقتباسات
Canadian journal of …
2022
6 اقتباسات
International journal of …
2020
32 اقتباسات
Pediatric gastroenterology, hepatology …
2020
20 اقتباسات
Pharmacological research
2018
132 اقتباسات
A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.
Meta-Analysis
BMC gastroenterology
2018
80 اقتباسات
United European gastroenterology …
2018
66 اقتباسات
Probiotics and antimicrobial …
2018
26 اقتباسات
World journal of …
2017
68 اقتباسات
Journal of pediatric …
2016
233 اقتباسات
Digestive diseases (Basel, …
2016
37 اقتباسات
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 اقتباسات
Journal of clinical …
2015
35 اقتباسات
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 اقتباسات
Nutricion hospitalaria
2015
5 اقتباسات
Medycyna wieku rozwojowego
2012
1 اقتباسات
Current opinion in …
2009
82 اقتباسات
Advances in biochemical …
2008
535 اقتباسات
The Journal of …
2007
265 اقتباسات
The American journal …
2006
918 اقتباسات
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 اقتباسات
Inflammation
2002
37 اقتباسات
The American journal …
2001
648 اقتباسات
Inflammation
2001
101 اقتباسات
The Journal of …
1999
559 اقتباسات
Pediatrics
1999
462 اقتباسات
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
الجرعات الشائعة
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
الحد الأعلى: Generally well-tolerated up to 40 billion CFU/day in clinical trials
الجرعات المدروسة في الأبحاث
| الجرعة | المدة | التأثير | ن |
|---|---|---|---|
| None | -- | Mixed | 279 |
| None | -- | Positive | -- |
| 10^9 CFU/day for 14 days | 2 weeks | Positive | 24 |
| None | -- | Mixed | -- |
| Probiotics (multi-strain) | -- | Positive | -- |
| S. boulardii CNCM I-745 | -- | Positive | -- |
| None | -- | Positive | -- |
| Twice daily | -- | Neutral | 2650 |
أفضل وقت للتناول: On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
الآثار الجانبية المُبلّغ عنها
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
التفاعلات المعروفة
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
الحد الأقصى المسموح به: Generally well-tolerated up to 40 billion CFU/day in clinical trials
استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.
Frequently Asked Questions
Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.
Related Evidence
مكونات أخرى لـ Antibiotic-Associated Diarrhea (AAD)
Lactobacillus rhamnosus GG لحالات أخرى
إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.